OC
LSTA icon

Oppenheimer & Co’s Lisata Therapeutics LSTA Stock Holding History

Oppenheimer & Co’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-323
Closed -$28K – 1292
2016
Q2 		$28K Sell
323
-20
-6% -$1.84K ﹤0.01% 1203
2016
Q1 		$39K Sell
343
-2
-0.6% -$197 ﹤0.01% 1215
2015
Q4 		$56K Buy
345
+136
+65% +$25K ﹤0.01% 1239
2015
Q3 		$47K Sell
209
-406
-66% -$102K ﹤0.01% 1306
2015
Q2 		$173K Buy
615
+233
+61% +$86.6K ﹤0.01% 1334
2015
Q1 		$145K Buy
+382
New +$207K ﹤0.01% 1371

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Oppenheimer & Co's LSTA Position: Q3 2016 in Review

Oppenheimer & Co sold out of Lisata Therapeutics (LSTA) in Q3 2016, closing a stake of 323 shares — an estimated $28K sold.

Oppenheimer & Co first reported a position in LSTA in Q1 2015 and held it in 6 quarters. The position peaked at $173K in Q2 2015. 28 funds tracked by Wall St. Rank hold LSTA as of Q3 2016.

  • Oppenheimer & Co reported no remaining Lisata Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Oppenheimer & Co sold 323 Lisata Therapeutics shares in Q3 2016, an estimated $28K.
  • Oppenheimer & Co first reported a position in Lisata Therapeutics in Q1 2015 and held it in 6 quarters.
  • Oppenheimer & Co's Lisata Therapeutics position peaked at $173K in Q2 2015.
  • 28 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2016.

Based on Oppenheimer & Co's 13F filing for Q3 2016, filed 7 Nov 2016.